60 http://clinicaloptions.com/Hepatitis.aspx en-us ℗ & © 2006 Clinical Care Options CCO is your best source for the newest HBV and HCV treatment data. Clinical Care Options Audio highlights from independent conference coverage and other Hepatitis educational programs Clinical Care Options Hepatitis vkeane@clinicaloptions.com Clinical Care Options CCO Independent Conference Coverage of the 2008 EASL Meeting in Milan Robert G. Gish, MD, discusses key presentations on insulin resistance, portal hypertension and cirrhosis, approved and investigational treatments for HCC, liver transplantation, and treatment of autoimmune hepatitis. http://clinicaloptions.com/hep_podcast_audio_milan2008_gish.mp3 Fri, 23 May 2008 17:00:00 GMT 09:49 hepatitis, EASL, Gish Clinical Care Options CCO Independent Conference Coverage of the 2008 EASL Meeting in Milan Stefan Zeuzem, MD, highlights data from EASL 2008 on 2 of the most clinically advanced classes of investigational hepatitis C agents-protease inhibitors and nucleoside polymerase inhibitors. http://clinicaloptions.com/hep_podcast_audio_milan2008_zeuzem.mp3 Thu, 22 May 2008 17:00:00 GMT 07:16 Hepatitis, HCV, Zeuzem Clinical Care Options CCO Independent Conference Coverage of the 2008 EASL Meeting in Milan Michael P. Manns, MD, highlights the clinical implications of trials performed in hepatitis C nonresponders and relapsers as well as results from a late-breaker presentation comparing the 2 available formulations of peginterferon. http://clinicaloptions.com/hep_podcast_audio_milan2008_manns.mp3 Wed, 21 May 2008 17:00:00 GMT 09:10 Hepatitis, HCV, Manns Clinical Care Options CCO Independent Conference Coverage of the 2008 EASL Meeting in Milan Maria Buti-Ferret, MD, discusses key efficacy and resistance HBV data presented at the meeting in Milan, including reports in treatment-naive patients and strategies for patients with resistance. http://clinicaloptions.com/hep_podcast_audio_milan2008_buti.mp3 Tue, 20 May 2008 17:00:00 GMT 11:37 hepatitis, HBV, Buti-Ferret Clinical Care Options Hepatitis Audio highlights from the 2007 meeting in Boston Emmet B. Keeffe, MD, MACP, discusses several topics of interest in the field of HBV treatment, in particular, data on the use of tenofovir for the treatment of chronic HBV therapy and long-term efficacy of entecavir and baseline predictive factors for long-term treatment efficacy of telbivudine. http://clinicaloptions.com/hep_podcast_audio_boston2007_keeffe.mp3 Fri, 30 Nov 2007 17:00:00 GMT 15:14 Hepatitis, HBV, Keeffe Clinical Care Options Hepatitis Audio highlights from the 2007 meeting in Boston Stephen A. Harrison, MD, LTC, MC, reviews key presentations from the Boston meeting related to insulin resistance, steatosis, and nonalcoholic steatohepatitis and their roles in the treatment of HCV. http://clinicaloptions.com/hep_podcast_audio_boston2007_harrison.mp3 Thu, 29 Nov 2007 17:00:00 GMT 10:17 Hepatitis, HCV, Harrison Clinical Care Options Hepatitis Audio highlights from the 2007 meeting in Boston Raymond T. Chung, MD, reports on the most important presentations from Boston concerning predicting response to approved HCV agents and improving response of patients with poor probability of achieving sustained virologic response. In addition, he summarizes several studies of retreatment strategies for previous nonresponders. http://clinicaloptions.com/hep_podcast_audio_boston2007_chung.mp3 Wed, 28 Nov 2007 17:00:00 GMT 9:31 Hepatitis, HCV, Chung Clinical Care Options Hepatitis Audio highlights from the 2007 meeting in Boston Nezam H. Afdhal, MD, FRCPI, discusses the key studies on investigational anti-HCV agents from the Boston meeting, focusing on specifically targeted small-molecule agents and an antiparasitic demonstrating anti-HCV activity. http://clinicaloptions.com/hep_podcast_audio_boston2007_afdhal.mp3 Tue, 27 Nov 2007 17:00:00 GMT 6:32 Hepatitis, HCV, Afdhdal Clinical Care Options Audio highlights from the 2007 EASL meeting in Barcelona Adrian M. Di Bisceglie, MD, FACP, discusses the top line HBV data presented at the meeting with particular focus on combination therapy and key outcomes in long-term follow-up of patients receiving peginterferon-based treatment. http://clinicaloptions.com/hep_podcast_audio_barcelona2007_dibisceglie.mp3 Wed, 9 May 2007 17:00:00 GMT 3:47 Hepatitis, HBV, Di Bisceglie Clinical Care Options Audio highlights from the 2007 EASL meeting in Barcelona Kris V. Kowdley, MD, FACP, discusses use of human albumin for the treatment of ascites and evaluation of liver stiffness scans to detect esophageal varices in HCV patients with advanced liver disease. http://clinicaloptions.com/hep_podcast_audio_barcelona2007_kowdley.mp3 Wed, 9 May 2007 17:00:00 GMT 3:59 Hepatitis, HCV, Kowdley Clinical Care Options Audio highlights from the 2007 EASL meeting in Barcelona Karen L. Lindsay, MD, MMM, discusses the key studies on anti-HCV agents and the future of combination HCV therapies including currently approved therapies, specifically targeted small molecule agents and other immunomodulatory agents in development. http://clinicaloptions.com/hep_podcast_audio_barcelona2007_lindsay.mp3 Wed, 9 May 2007 17:00:00 GMT 11:06 Hepatitis, HCV, Lindsay Clinical Care Options Audio highlights from the Boston meeting Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses several topics of interest in the field of HBV treatment. In particular data on the benefits of extension of entecavir therapy; optimization of therapy based on early viral suppression; long term benefit of 48 week pegylated interferon treatment, and incidence and role of resistance in treatment modification are reviewed. http://clinicaloptions.com/hep_podcast_audio_boston2006_dusheiko.mp3 Tue, 7 Nov 2006 17:00:00 GMT 9:35 Hepatitis, HBV, Dusheiko Clinical Care Options Audio highlights from the Boston meeting Nezam H. Afdhal, MD, FRCPI, discusses the top line HCV data presented at the meeting with particular focus on specifically targeted antiviral therapy for HCV and how to combine novel therapeutics with other agents both approved and those in clinical development. http://clinicaloptions.com/hep_podcast_audio_boston2006_afdhal.mp3 Tue, 7 Nov 2006 17:00:00 GMT 5:15 Hepatitis, HCV, Afdhal Clinical Care Options Audio highlights from the Boston meeting Raymond T. Chung, MD, describes a new agent for the treatment of HCV/HIV coinfection, survival and prognostic factors in a cohort of HCV/HIV coinfected individuals, and the use of HCC down-staging to obtain transplantation candidacy. http://clinicaloptions.com/hep_podcast_audio_boston2006_chung.mp3 Tue, 7 Nov 2006 17:00:00 GMT 11:15 Hepatitis, HIV coinfection, Chung Clinical Care Options Expert Highlights from the 2006 EASL Meeting in Vienna Stephanos J. Hadziyannis, MD, discusses the principles and practice behind the most important presentations in hepatitis C virus and hepatitis B virus management at EASL. http://clinicaloptions.com/hep_podcast_audio_vienna06_hcvhbv.mp3 Sat, 6 May 2006 17:00:00 GMT 4:08 hepatitis, HBV, HCV, Hadziyannis, liver Clinical Care Options Expert Highlights from the 2006 European liver meeting in Vienna Yves Benhamou, MD, provides a perspective on improvements in hepatitis B virus therapy and future directions in the field. http://clinicaloptions.com/hep_podcast_audio_vienna06_hbv.mp3 Tue, 2 May 2006 17:00:00 GMT 6:17 hepatitis, HBV, Benhamou, liver Clinical Care Options Expert Highlights from the Shanghai-Hong Kong International Liver Congress 2006 Sum P. Lee, MD, describes the role of genomics and proteomics in the future treatment of HCC, and summarizes data on hepatitis E virus infection in high-risk areas of the world. http://clinicaloptions.com/hep_podcast_audio_Shanghai06_lee.mp3 Mon, 17 Apr 2006 17:00:00 GMT 3:59 hepatitis, HBV, Lee, Shanghai, liver Clinical Care Options Expert Highlights from the Shanghai-Hong Kong International Liver Congress 2006 Sum P. Lee, MD, describes the role of genomics and proteomics in the future treatment of HCC, and summarizes data on hepatitis E virus infection in high-risk areas of the world. http://clinicaloptions.com/hep_podcast_audio_Shanghai06_lee.mp3 Mon, 17 Apr 2006 17:00:00 GMT 3:59 hepatitis, HBV, Lee, Shanghai, liver Clinical Care Options Expert Highlights from the Shanghai-Hong Kong International Liver Congress 2006 George K.K. Lau, MD, reviews the importance of scientific interactions among the international treatment community in meeting the challenges of liver disease prevention and treatment. http://clinicaloptions.com/hep_podcast_audio_Shanghai06_lau.mp3 Thu, 13 Apr 2006 17:00:00 GMT 1:50 hepatitis, HBV, Lau, Shanghai, liver Clinical Care Options Expert Highlights from the Shanghai-Hong Kong International Liver Congress 2006 Anna S.F. Lok, MD, provides a review of the advantages and disadvantages of current and investigational treatment strategies for chronic hepatitis B. http://clinicaloptions.com/hep_podcast_audio_Shanghai06_lok.mp3 Mon, 10 Apr 2006 17:00:00 GMT 2:23 hepatitis, HBV, Lok, Shanghai, liver Clinical Care Options Independent highlights from the hepatitis meeting in San Francisco Robert G. Gish, MD, provides an overview of the data from key studies in HBV presented at the conference. http://clinicaloptions.com/hep_podcast_audio_SF05_gish.mp3 Mon, 13 Feb 2006 17:00:00 GMT 3:39 hepatitis, HBV, Gish Clinical Care Options Independent highlights from the hepatitis meeting in San Francisco Mitchell L. Shiffman, MD, reviews the latest antiviral therapies, and high-dose treatment strategies for the management of HCV infection. http://clinicaloptions.com/hep_podcast_audio_SF05_shiffman.mp3 Mon, 13 Feb 2006 17:00:00 GMT 2:05 hepatitis, HCV, Shiffman Clinical Care Options Independent highlights from the hepatitis meeting in San Francisco Raymond T. Chung, MD, discusses the issue of acute HCV infection in HIV-infected patients. http://clinicaloptions.com/hep_podcast_audio_SF05_chung.mp3 Mon, 13 Feb 2006 17:00:00 GMT 4:37 hepatitis, HCV, HIV, coinfection, Chung Clinical Care Options Independent highlights from the hepatitis meeting in San Francisco Mark S. Sulkowski, MD, discusses the effects of interferon treatment on fibrosis in HCV/HIV coinfected patients. http://clinicaloptions.com/hep_podcast_audio_SF05_sulkowski.mp3 Mon, 13 Feb 2006 17:00:00 GMT 1:50 hepatitis, HCV, HIV, coinfection, fibrosis, interferon, Sulkowski Clinical Care Options Independent highlights from the AASLD 2008 meeting in San Francisco Stefan Zeuzem, MD, highlights data from AASLD 2008 on investigational agents for viral hepatitis, focusing on new targeted therapies for hepatitis C, as well as markers for HBsAg seroconversion with peginterferon. http://clinicaloptions.com/hep_podcast_audio_sanfrancisco2008_zeuzem.mp3 Mon, 24 Nov 2008 17:00:00 GMT 9:07 hepatitis, AASLD, zeuzem Clinical Care Options Independent highlights from the AASLD 2008 meeting in San Francisco Robert G. Gish, MD, reviews data from AASLD 2008 on frontline hepatitis B treatment options with approved agents and predicting response based on patient and viral characteristics. http://clinicaloptions.com/hep_podcast_audio_sanfrancisco2008_Gish.mp3 Mon, 24 Nov 2008 17:00:00 GMT 11:08 hepatitis, AASLD, Gish Clinical Care Options Independent highlights from the AASLD 2008 meeting in San Francisco Gregory T. Everson, MD, FACP, discusses data from AASLD 2008 on strategies for improving hepatitis C treatment response with approved agents and predicting response based on various possible responses and assays. http://clinicaloptions.com/hep_podcast_audio_sanfrancisco2008_Everson.mp3 Mon, 24 Nov 2008 17:00:00 GMT 3:55 hepatitis, AASLD, Everson